Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Bayer Yakuhin said on October 29 that its oral tyrosine kinase inhibitor Hyrnuo (sevabertinib) is now available in Japan for the treatment of unresectable advanced or recurrent HER2 (ERBB2)-mutated non-small cell lung cancer (NSCLC). Hyrnuo became Japan’s first molecularly targeted…
To read the full story
Related Article
BUSINESS
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026





